Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors

NCT05395052 is registered in ClinicalTrials.gov with Fate Therapeutics as lead sponsor.

NCT NCT05395052
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05395052 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-Label, Multicenter Study of FT536 as Monotherapy and in Combination With Monoclonal Antibodies in Subjects With Advanced Solid Tumors
Lead sponsor
Fate Therapeutics
Phase
Phase 1
Overall status
Terminated
Start date
May 31, 2022
Completion date
August 11, 2023
Enrollment
5 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, colorectal cancer, gastroesophageal cancer, head and neck cancer, non small cell lung cancer, ovarian cancer, pancreatic cancer